Patients
Tumors, active malignancies
METASTASIS, CARDIOVASCULAR DISEASE, DISEASE, TUMORS, CERVICAL CANCER, ONCOLOGY, CPS, AUTOIMMUNE DISEASE
Eligible patients were aged 18–75 years, had histologically or cytologically diagnosed, PD-L1–positive (combined positive score [CPS] ≥1) cervical cancer, and experienced progressive disease or relapse after receiving standard treatment or were intolerant to first-line chemotherapy. Patients must have at least one measurable lesion per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; an Eastern Cooperative Oncology Group (ECOG) performance status score (PS) of 0 or 1; adequate hematologic, renal, and hepatic function; and a life expectancy of ≥12 weeks.Key exclusion criteria included prior nab-paclitaxel treatment, prior immune checkpoint inhibitor therapy, active malignancies, central nervous system or leptomeningeal metastasis, preparing to or have received an organ or bone marrow transplant, significant cardiovascular disease, and a history of autoimmune disease. The full list of inclusion and exclusion criteria is provided in the The trial was registered with 